Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger (SDGR) has granted inducement equity awards to its newly appointed EVP, Chief Commercial Officer, Global Head of Software Sales & Marketing, Mannix Aklian, who joined on May 28, 2025. The compensation package includes a non-statutory stock option to purchase 84,375 shares at $21.44 per share and 14,063 restricted stock units (RSUs). The stock options have a ten-year term with 25% vesting after one year and the remainder vesting monthly over three years. The RSUs vest over four years, with 25% vesting after the first year and the remaining vesting annually over three years.

Schrödinger (NASDAQ: SDGR) has appointed Mannix Aklian as Executive Vice President, Chief Commercial Officer, and Global Head of Software Sales and Marketing. With over 25 years of experience in software sales and leadership within biopharmaceutical and technology industries, Aklian will oversee global account management teams and drive the company's software business growth. He joins from Certara, where he served as Senior Vice President of Global Software Sales, and previously held the position of CEO at LI, Inc. Aklian holds both B.S. and M.S. degrees in Molecular Biology from Tufts University.

Schrödinger (NASDAQ: SDGR) has granted restricted stock units (RSUs) for 7,051 shares to seven newly hired employees on May 21, 2025. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee. The RSUs follow a four-year vesting schedule: 25% vests after 12 months of continuous service, followed by equal yearly installments of 1/4 over the next three years. These grants serve as material inducement for employment compensation and comply with Nasdaq Listing Rule 5635(c)(4).

Schrödinger (SDGR) announced its upcoming participation in the Jefferies Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, June 4, 2025, at 1:25 p.m. ET. Investors and interested parties can access the live webcast through the "Investors" section of Schrödinger's website. The presentation recording will remain available on the company's website for approximately 90 days after the event.

Schrödinger (SDGR) announced upcoming presentations of initial Phase 1 clinical data for SGR-1505, their investigational MALT1 inhibitor, at two major conferences. The data will be presented at the European Hematology Association Annual Congress (June 12-15, 2025, Milan) and the International Conference on Malignant Lymphoma (June 17-21, 2025, Lugano).

The Phase 1 study evaluates SGR-1505's safety, tolerability, and anti-tumor activity in patients with relapsed/refractory B-cell malignancies. The presentations will include initial safety, pharmacokinetic and pharmacodynamic data, plus preliminary efficacy data across various dosing levels. The company will host a webcast to discuss the data on June 12, 2025, at 8:00 a.m. ET.

Schrödinger (NASDAQ: SDGR) announced its upcoming participation in the BofA Securities 2025 Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, May 14, 2025, at 4:40 p.m. ET. Interested parties can access the live webcast through the "Investors" section of Schrödinger's website, where it will remain available for approximately 90 days after the event.

Schrödinger (SDGR) presented preclinical data for two cancer drug candidates at the AACR Annual Meeting 2025. The first candidate, SGR-3515, a Wee1/Myt1 co-inhibitor, showed improved anti-tumor activity compared to existing monotherapy inhibitors, with optimized dosing schedules allowing efficacy preservation while minimizing side effects. Initial Phase 1 trial data for SGR-3515 in advanced solid tumors is expected in H2 2025.

The second candidate, SGR-4174, a novel SOS1 inhibitor targeting KRAS mutations, demonstrated high selectivity and strong tumor growth inhibition both as monotherapy and in combination with MEK or KRAS inhibitors. The company also presented data on a new computational method for predicting responses to Wee1-based drug combinations, particularly in head and neck cancers.